<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Beatriz E Marciano, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christa S Zerbe, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven M Holland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>There are a small number of well-described genetic defects in hematopoietic cell enzymes or transporter proteins that result in neutrophil dysfunction and immunodeficiency. Two of these, myeloperoxidase (MPO) deficiency and glucose-6-phosphate dehydrogenase (G6PD) deficiency, are relatively common. The others presented in this topic review, glutathione reductase (GR) deficiency, glutathione synthetase (GS) deficiency, and glycogen storage disease type Ib (GSD Ib), are rare.</p><p>This topic review provides an overview of the genetic defects responsible for each of these disorders, the underlying mechanism of neutrophil or leukocyte dysfunction in each condition that leads to immunodeficiency, and the clinical manifestations, diagnosis, and treatment for each disorder.</p><p>G6PD deficiency and glucose-6 phosphatase deficiency are mentioned briefly here and discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a> and  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MYELOPEROXIDASE DEFICIENCY</span><span class="headingEndMark"> — </span>MPO deficiency (MIM #254600) is an autosomal recessive inherited disorder with a variable clinical phenotype. It is also the most common primary phagocyte disorder [<a href="#rid1">1-4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>1 in 4000 persons have complete MPO deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>1 in 2000 have a partial defect</p><p></p><p class="headingAnchor" id="H1315995415"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>MPO is encoded by a gene located at 17q23. MPO deficiency can either be inherited or acquired. The hereditary form is the most frequent. Primary (inherited) MPO deficiency has variable expression and penetrance. A number of germline pathogenic variants result in primary MPO deficiency. Some of these cause defective posttranslational processing of the MPO precursor protein, while pathogenic variants in the regulatory region cause pretranslational defects [<a href="#rid5">5</a>]. MPO loss-of-function genetic mutations are associated with increased neutrophil counts and inflammatory pustular skin disease [<a href="#rid6">6</a>]. The mechanism of development of an acquired MPO deficiency, observed in patients with hematopoietic stem cell neoplasms such as myelofibrosis, is unknown [<a href="#rid7">7-9</a>], except for a report of homozygous calreticulin mutations leading to acquired MPO deficiency in patients with Philadelphia chromosome-negative myeloproliferative neoplasms [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Biology of myeloperoxidase</span><span class="headingEndMark"> — </span>MPO is a tetramer of 150 kDa consisting of two heavy chains, two light chains, and two iron atoms. MPO is synthesized in neutrophils and monocytes, packaged in azurophilic (primary) granules, and released either into the phagosome or the extracellular space. MPO is the most abundant enzyme in the azurophilic granules and plays a critical role in bacterial killing by neutrophils. Deficient cells take approximately twice as long as normal cells to kill pathogens in vitro [<a href="#rid10">10,11</a>]. MPO serves many other roles in the human organism. It is important in the homeostasis of reactive oxidants and also can act as both a proinflammatory and an antiinflammatory mediator [<a href="#rid12">12</a>].</p><p>MPO catalyzes the conversion of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) to hypohalous acid (in neutrophils, the halide is chloride [Cl-] and the acid is bleach)  (<a class="graphic graphic_figure graphicRef72548" href="/z/d/graphic/72548.html" rel="external">figure 1</a>). This reaction is thought to amplify the toxicity of the reactive oxygen species generated during the respiratory burst against bacteria and fungi.</p><p>Neutrophils release neutrophil extracellular traps (NETs), structures composed of decondensed chromatin and granule proteins that are thought to trap and kill pathogens, as part of their extracellular killing tools. Reactive oxygen species are required to initiate NET formation. Neutrophil elastase and MPO synergize to drive chromatin decondensation, contributing to this mechanism of extracellular killing of microorganisms [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The majority of patients with MPO deficiency are asymptomatic, even though in vitro studies reveal that MPO-deficient neutrophils are markedly less efficient than normal neutrophils in killing <em>Candida albicans</em> and hyphal forms of <em>Aspergillus fumigatus</em> [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Fungal infections</span><span class="headingEndMark"> — </span>Infections due to different <em>Candida</em> strains are the most frequently reported clinical finding in the small percentage of patients with MPO deficiency who are symptomatic. Mucocutaneous, meningeal, and bone infections, as well as sepsis, have been described [<a href="#rid4">4,16-20</a>]. The presence of diabetes mellitus [<a href="#rid1">1,21,22</a>] or cancer [<a href="#rid23">23,24</a>] appears to increase the risk for <em>Candida</em> infections in patients with MPO deficiency. Patients with MPO deficiency do not generally develop invasive aspergillosis, indicating the existence of a critical MPO-independent system.</p><p class="headingAnchor" id="H6"><span class="h3">Noninfectious diseases</span><span class="headingEndMark"> — </span>MPO deficiency is associated with an increased risk for chronic inflammatory diseases (eg, polyarthritis, autoimmune lupus nephritis, diabetes mellitus) due to its role as an antiinflammatory mediator [<a href="#rid12">12,25</a>]. This is consistent with the finding that anti-MPO antibodies are strongly associated with vasculitis (eg, granulomatosis with polyangiitis and microscopic polyangiitis) (see  <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies"</a>). However, MPO deficiency may also have beneficial effects, which is an expanding area of investigation [<a href="#rid25">25-27</a>]. As examples, MPO deficiency may protect against cardiovascular damage, progression of chronic kidney disease, and skin injury due to an acute inflammatory response [<a href="#rid28">28-30</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>MPO deficiency is one of the diagnoses that should be suspected in patients with unexplained, recurrent, invasive <em>Candida</em> infections. However, the vast majority of patients with MPO deficiency never develop invasive <em>Candida</em> infections. Definitive diagnosis is established by histochemical staining of neutrophils for MPO, which is available through commercial labs. The clinical relevance of identifying MPO deficiency in a particular patient, however, is less straightforward. Because so many patients with MPO deficiency are completely asymptomatic, patients with recurrent mucocutaneous candidiasis should be carefully evaluated for acquired immunodeficiency states, such as diabetes mellitus and human immunodeficiency virus (HIV) infection, as well as other primary immune defects, even if MPO deficiency is identified.</p><p>MPO deficiency was previously a common incidental finding because the machines that performed automated leukocyte differential counts used to rely upon staining for MPO activity to obtain the neutrophil count [<a href="#rid31">31</a>]. Patients with MPO deficiency had populations of "large unstained cells" in their automated differential counts that were not borne out by manual performance of the differential count. Additionally, patients with MPO deficiency are sometimes erroneously diagnosed with chronic granulomatous disease (CGD) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H1767115729"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis in a patient with invasive <em>Candida</em> infections, without external immune suppression, includes CGD and autosomal dominant signal transducer and activator of transcription (STAT) 3 deficiency (Job syndrome or autosomal dominant hyperimmunoglobulin E syndrome [HIES]), STAT1 gain of function, and autoimmune polyendocrinopathy-candidiasis-ectodermal dysplasia (APECED) [<a href="#rid33">33</a>]. Complete MPO deficiency causes an abnormal dihydrorhodamine oxidation (DHR) test [<a href="#rid32">32</a>] and may therefore be misdiagnosed as CGD. (See  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/3960.html" rel="external">"Autosomal dominant hyperimmunoglobulin E syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">"Approach to the child with recurrent infections"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>There is no specific treatment for MPO deficiency. Infections should be aggressively treated when they occur, and control of blood glucose may be beneficial in patients with associated diabetes. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY</span><span class="headingEndMark"> — </span>Glucose-6-phosphate dehydrogenase (G6PD; Xq28) deficiency (MIM #305900) is the most common enzymopathy in humans, affecting 400 million persons worldwide. However, most persons with G6PD deficiency are asymptomatic. There are five classes of variants based upon the functional severity of the deficiency, with class I characterized by severe deficiency resulting in chronic, nonspherocytic, hemolytic anemia, ranging to class V with greater than 150 percent of normal activity [<a href="#rid34">34,35</a>].</p><p>G6PD is required for nicotinamide adenine dinucleotide phosphate (NADPH) generation through the hexose monophosphate pathway. NADPH is necessary for the respiratory burst and is also crucial in preserving red blood cells from oxidative damage  (<a class="graphic graphic_figure graphicRef72548" href="/z/d/graphic/72548.html" rel="external">figure 1</a>). However, neutrophil dysfunction in G6PD deficiency is less frequent than expected. This may be because most affected patients have more than 20 percent of G6PD activity in neutrophils, a threshold sufficient to maintain the respiratory burst within the normal range [<a href="#rid36">36,37</a>].</p><p>Rarely, patients with severe G6PD deficiency (less than 5 percent of the enzyme activity in neutrophils) have increased susceptibility to infections due to impairment of the neutrophil respiratory burst. Recurrent bacterial pulmonary infections and one death due to <em>Chromobacterium violaceum </em>sepsis have been described [<a href="#rid36">36-43</a>]. G6PD deficiency predisposes to septic complications and anemia in patients who have suffered severe traumatic injuries. This is accompanied by increased monocyte oxidative stress, decreased apoptotic response, increased cell adhesion, and diminished interleukin (IL) 10 response [<a href="#rid44">44</a>]. Prophylactic antibiotics (eg, cephalosporins, quinolones) may be helpful in the few cases with recurrent infections. Cotrimoxazole should be avoided as it may exacerbate hemolysis in G6PD deficiency. As in other primary phagocyte immunodeficiencies, infections must be aggressively treated. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p>G6PD deficiency is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7109.html" rel="external">"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">GLUTATHIONE PATHWAY ALTERATIONS</span><span class="headingEndMark"> — </span>The reduced form of glutathione (GSH) protects cells from the deleterious effects of reactive oxygen species that are produced during the respiratory burst and the metabolism of uric acid. In neutrophils, GSH is critical for preserving nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.</p><p>Glutathione reductase (GR; 8p21.1) and glutathione synthetase (GS; 20q11.2) are involved in maintaining adequate intracellular levels of GSH  (<a class="graphic graphic_figure graphicRef72548" href="/z/d/graphic/72548.html" rel="external">figure 1</a>) [<a href="#rid36">36</a>]. GR deficiency (MIM #138300) and GS deficiency (MIM #266130, #231900) are rare, autosomal recessive inherited diseases. (See  <a class="medical medical_review" href="/z/d/html/7128.html" rel="external">"Rare RBC enzyme disorders"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Both GR and GS deficiencies are associated with hemolysis after increased oxidant stress such as infection, diet, and certain medications such as <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> and sulfa-based medications, as well as <a class="drug drug_general" data-topicid="9810" href="/z/d/drug information/9810.html" rel="external">primaquine</a>  (<a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">table 1</a>). GS- but not GR-deficient patients have an increased risk of infections.</p><p class="headingAnchor" id="H16"><span class="h3">Glutathione synthetase deficiency</span><span class="headingEndMark"> — </span>Mild, moderate, and severe clinical presentations are described for GS deficiency. Mutations causing frameshifts, premature stop codons, or aberrant splicing are associated with moderate or severe clinical phenotypes [<a href="#rid45">45</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Mildly affected patients have isolated hemolytic anemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderately affected patients have hemolytic anemia and metabolic acidosis with increased 5-oxoproline levels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severely affected patients have hemolytic anemia, metabolic acidosis with increased 5-oxoproline levels, and progressive dysfunction of the central nervous system (CNS). These patients also have recurrent bacterial infections. Impairments in phagocytosis and intracellular bacterial killing have been described [<a href="#rid46">46-48</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Glutathione reductase deficiency</span><span class="headingEndMark"> — </span>Premature termination of the respiratory burst is described in patients with GR deficiency. These patients have hemolytic anemia, but no increased infection rate has been reported.</p><p class="headingAnchor" id="H18"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnoses of GS and GR deficiency are based upon the presence of characteristic clinical manifestations (hemolytic anemia with or without metabolic acidosis, progressive neurodevelopmental defects, and recurrent bacterial infections) and results of specific laboratory tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with GS deficiency present with elevated 5-oxoprolinuria (pyroglutamic aciduria) in the urine and low GSH in erythrocytes (as measured by a standard colorimetric test). GS activity in cultured fibroblasts can also be measured.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GR activity is low in GR deficiency and can be measured in red cell hemolysates both in the presence or absence of flavin adenine dinucleotide (FAD).</p><p></p><p>The abovementioned tests are commercially available, although the number of laboratories performing them is small [<a href="#rid49">49</a>].</p><p>Neonatal screening for GS deficiency is effective since the most important determinants for outcome and survival in these patients are early diagnosis and initiation of treatment [<a href="#rid50">50</a>].</p><p>In children who present with early-onset hemolysis, metabolic acidosis, and neurologic changes, the differential diagnosis includes other inborn errors of metabolism such as X-linked ornithine transcarbamylase deficiency, urea cycle defects, tyrosinemia, and homocystinuria [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Exposure to drugs and chemicals with oxidant potential should be avoided, as in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency  (<a class="graphic graphic_table graphicRef74254" href="/z/d/graphic/74254.html" rel="external">table 1</a>). Daily supplementation with <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> 400 international units has shown neutrophil functional improvement in vitro and reduced infection rates in patients with GS deficiency in vivo [<a href="#rid52">52,53</a>]. As in other primary phagocyte immunodeficiencies, infections must be aggressively treated. (See  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">GLYCOGEN STORAGE DISEASE Ib</span><span class="headingEndMark"> — </span>Glycogen storage disease (GSD) type Ib (MIM #232200) is characterized by the inability to convert glucose-6-phosphate to glucose within the liver due to an autosomal recessive defect in the glucose-6-phosphate transporter 1 (also called the G6P translocase) encoded on chromosome 11q23 [<a href="#rid54">54</a>]. The incidence of GSD I is 1 in 100,000 livebirths [<a href="#rid55">55</a>]. GSD Ib may present early in life with fasting hypoglycemia, lactic acidosis, hyperuricemia, hyperlipidemia, hepatomegaly, and seizures, as well as neutropenia and neutrophil dysfunction with recurrent sinopulmonary infections. (See  <a class="medical medical_review" href="/z/d/html/8373.html" rel="external">"Congenital neutropenia"</a> and  <a class="medical medical_review" href="/z/d/html/8388.html" rel="external">"Laboratory evaluation of neutrophil disorders"</a>.)</p><p>Deficient neutrophil chemotaxis and defective respiratory burst result in an increased incidence of infections [<a href="#rid56">56,57</a>]. In one study, 15 of 21 subjects with GSD Ib deficiency had moderate-to-severe infections, which were primarily due to bacteria affecting the ears, lungs, and skin. However, in a study of 25 GSD Ib patients, no correlation was found between individual pathogenic variants and the presence of neutropenia, bacterial infections, and systemic complications [<a href="#rid55">55</a>]. Therefore, background genetics and other influences likely modulate neutrophil differentiation, maturation, and apoptosis and thus the severity and frequency of infections.</p><p>The diagnosis of GSD Ib should be considered in patients with any combination of the characteristic clinical manifestations, including lactic acidosis, hyperlipidemia, neutropenia, neutrophil dysfunction, and an increased rate of infections. These patients can have oral disease, ranging from ulcers to severe periodontal disease [<a href="#rid58">58</a>]. Increased autoimmunity including inflammatory bowel disease [<a href="#rid8">8</a>], Crohn disease [<a href="#rid59">59,60</a>], thyroid autoimmunity [<a href="#rid61">61</a>], and myasthenia gravis [<a href="#rid62">62</a>] has been reported in patients with GSD Ib. Identification of pathogenic variants confirms the diagnosis [<a href="#rid54">54</a>].</p><p>Recombinant human granulocyte colony-stimulating factor (G-CSF) has been used successfully to counter neutropenia and immune dysfunction, as well as improve the symptoms of inflammatory bowel disease [<a href="#rid63">63-66</a>]. In a study of seven patients with severe and/or recurrent bacterial infections, G-CSF at a median dose of 5 mcg/kg per day increased the absolute neutrophil count in six and prevented recurrent infection in all seven [<a href="#rid65">65</a>]. The use of G-CSF may also improve phagocytic function through calcium mobilization and superoxide anion generation, although defective neutrophil chemotaxis persisted after G-CSF treatment in one study [<a href="#rid64">64</a>]. Splenomegaly is a potential consequence of G-CSF therapy. All 13 patients in one study developed splenomegaly [<a href="#rid63">63</a>], but this was mild in five individuals, and none required splenectomy. A review of 103 adults and children with GSD Ib who received low-dose G-CSF revealed that, overall, there was a decrease in severity and frequency of infections and an improvement in enterocolitis and cytopenia [<a href="#rid67">67</a>]. However, even at low doses 1 to 2 mcg/kg/day, 70 percent of patients had worsening splenomegaly. Abdominal pain and early satiety also limited therapy with G-CSF. There are reports of several cases of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) developing in GDS Ib patients after receiving long-term therapy with G-CSF [<a href="#rid68">68-70</a>]. Monitoring long-term response to G-CSF is critical given these reports. As in other primary phagocyte immunodeficiencies, infections, when present, should be aggressively treated. (See  <a class="medical medical_review" href="/z/d/html/3948.html" rel="external">"Inborn errors of immunity (primary immunodeficiencies): Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/3913.html" rel="external">"Primary disorders of phagocyte number and/or function: An overview"</a>.)</p><p>Preliminary evidence suggests that <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a> has the potential to become the first-line treatment for neutropenia and neutrophil dysfunction-related symptoms in persons with GSD Ib [<a href="#rid71">71</a>]. Dietary therapy maintains the patient's blood glucose levels and reduces the early symptoms. However, long-term complications such as hepatocellular adenoma (HCA), hepatocellular carcinoma (HCC), and kidney failure still occur. Liver-directed gene therapy in a GSD Ib mouse model showed promise in correcting metabolic abnormalities and preventing development of HCA, but did not correct myeloid and kidney dysfunction [<a href="#rid71">71-74</a>].</p><p>GSD Ib is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a>.)</p><p class="headingAnchor" id="H1783770761"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Genetic defects in hematopoietic cell enzymes or transporter proteins can cause neutrophil dysfunction and immunodeficiency. Myeloperoxidase (MPO) deficiency and glucose-6-phosphate dehydrogenase (G6PD) deficiency are relatively common disorders, while others are rare. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myeloperoxidase deficiency</strong> – MPO deficiency is the most common primary disorder of phagocytes, although the vast majority of affected individuals are asymptomatic. Recurrent <em>Candida</em> infections are seen in the small number of patients who do manifest symptoms, and MPO deficiency may play a role in the development of <em>Candida</em> infections in patients with diabetes mellitus or malignancies. The diagnosis is established genetically or by histochemical staining of neutrophils for MPO, and there is no specific corrective therapy. (See <a class="local">'Myeloperoxidase deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucose-6-phosphate deficiency</strong> – G6PD deficiency is the most common enzymopathy in humans. G6PD is necessary for the neutrophil respiratory burst and also protects red blood cells from oxidative damage. It is an X-linked disorder that most often presents with hemolytic anemia. Patients with severe deficiency may have increased susceptibility to bacterial infections and sepsis. Treatment of immune dysfunction may include prophylactic antibiotics and aggressive treatment of infections. (See <a class="local">'Glucose-6-phosphate dehydrogenase deficiency'</a> above and  <a class="medical medical_review" href="/z/d/html/7109.html" rel="external">"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a> and  <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glutathione pathway deficiencies</strong> – Deficiencies of glutathione reductase (GR) and glutathione synthetase (GS) are extremely rare, autosomal recessive diseases. Severe GS deficiency may present with hemolytic anemia, metabolic acidosis, progressive central nervous system (CNS) defects, and recurrent bacterial infections. Daily <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> supplementation can improve neutrophil function in GS deficiency. Infections are not a feature of GR deficiency. (See <a class="local">'Glutathione pathway alterations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glycogen storage disease Ib</strong> – GSD Ib is a rare, recessive disorder that presents in childhood with fasting hypoglycemia, lactic acidosis, hyperuricemia, hyperlipidemia, hepatomegaly, seizures, neutropenia, and neutrophil dysfunction. Sinopulmonary infections and mucosal ulcers are observed, and there is associated inflammatory bowel disease. The diagnosis is made by genetic analysis. Treatment involves maintaining normal blood glucose levels, and granulocyte colony-stimulating factor (G-CSF) therapy improves immune function. (See <a class="local">'Glycogen storage disease Ib'</a> above and  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a>.)</p><p></p><p class="headingAnchor" id="H3232017833"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Sergio D Rosenzweig, MD, who contributed as an author to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parry MF, Root RK, Metcalf JA, et al. Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 1981; 95:293.</a></li><li><a class="nounderline abstract_t">Kitahara M, Eyre HJ, Simonian Y, et al. Hereditary myeloperoxidase deficiency. Blood 1981; 57:888.</a></li><li><a class="nounderline abstract_t">Nauseef WM, Root RK, Malech HL. Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency. J Clin Invest 1983; 71:1297.</a></li><li><a class="nounderline abstract_t">Klebanoff SJ, Kettle AJ, Rosen H, et al. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol 2013; 93:185.</a></li><li><a class="nounderline abstract_t">Marchetti C, Patriarca P, Solero GP, et al. Genetic characterization of myeloperoxidase deficiency in Italy. Hum Mutat 2004; 23:496.</a></li><li><a class="nounderline abstract_t">Vergnano M, Mockenhaupt M, Benzian-Olsson N, et al. Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. Am J Hum Genet 2020; 107:539.</a></li><li><a class="nounderline abstract_t">Lanza F. Clinical manifestation of myeloperoxidase deficiency. J Mol Med (Berl) 1998; 76:676.</a></li><li><a class="nounderline abstract_t">Bendix-Hansen K. Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): Incidence in untreated myeloproliferative disorders. Scand J Haematol 1986; 36:8.</a></li><li><a class="nounderline abstract_t">Theocharides AP, Lundberg P, Lakkaraju AK, et al. Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood 2016; 127:3253.</a></li><li class="breakAll">Stiehm ER, Ochs HD, Winkelstein JA. The natural (innate) defense system. In: Immunologic disorders in infants and children, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.258.</li><li><a class="nounderline abstract_t">Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92:3007.</a></li><li><a class="nounderline abstract_t">Odobasic D, Kitching AR, Holdsworth SR. Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase. J Immunol Res 2016; 2016:2349817.</a></li><li><a class="nounderline abstract_t">Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010; 191:677.</a></li><li><a class="nounderline abstract_t">Rex JH, Bennett JE, Gallin JI, et al. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 1990; 162:523.</a></li><li><a class="nounderline abstract_t">Diamond RD, Clark RA, Haudenschild CC. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Invest 1980; 66:908.</a></li><li><a class="nounderline abstract_t">Weber ML, Abela A, de Repentigny L, et al. Myeloperoxidase deficiency with extensive candidal osteomyelitis of the base of the skull. Pediatrics 1987; 80:876.</a></li><li><a class="nounderline abstract_t">Okuda T, Yasuoka T, Oka N. Myeloperoxidase deficiency as a predisposing factor for deep mucocutaneous candidiasis: a case report. J Oral Maxillofac Surg 1991; 49:183.</a></li><li><a class="nounderline abstract_t">Ludviksson BR, Thorarensen O, Gudnason T, Halldorsson S. Candida albicans meningitis in a child with myeloperoxidase deficiency. Pediatr Infect Dis J 1993; 12:162.</a></li><li><a class="nounderline abstract_t">Nguyen C, Katner HP. Myeloperoxidase deficiency manifesting as pustular candidal dermatitis. Clin Infect Dis 1997; 24:258.</a></li><li><a class="nounderline abstract_t">Chiang AK, Chan GC, Ma SK, et al. Disseminated fungal infection associated with myeloperoxidase deficiency in a premature neonate. Pediatr Infect Dis J 2000; 19:1027.</a></li><li><a class="nounderline abstract_t">Lehrer RI, Cline MJ. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 1969; 48:1478.</a></li><li><a class="nounderline abstract_t">Cech P, Stalder H, Widmann JJ, et al. Leukocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess. Am J Med 1979; 66:149.</a></li><li><a class="nounderline abstract_t">Koziol-Montewka M, Magrys A, Paluch-Oles J, et al. MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection. Immunol Invest 2006; 35:167.</a></li><li><a class="nounderline abstract_t">Magrys A, Koziol-Montewka M, Staroslawska E, et al. Immunological parameters of candidiasis in cancer patients. New Microbiol 2005; 28:355.</a></li><li><a class="nounderline abstract_t">Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ? Acta Haematol 2000; 104:10.</a></li><li><a class="nounderline abstract_t">Hoy A, Leininger-Muller B, Kutter D, et al. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002; 40:2.</a></li><li><a class="nounderline abstract_t">Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007; 219:88.</a></li><li><a class="nounderline abstract_t">Jain AK, Tewari-Singh N, Inturi S, et al. Myeloperoxidase deficiency attenuates nitrogen mustard-induced skin injuries. Toxicology 2014; 320:25.</a></li><li><a class="nounderline abstract_t">Lehners A, Lange S, Niemann G, et al. Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice. Am J Physiol Renal Physiol 2014; 307:F407.</a></li><li><a class="nounderline abstract_t">Golubinskaya V, Brandt-Eliasson U, Gan LM, et al. Endothelial function in a mouse model of myeloperoxidase deficiency. Biomed Res Int 2014; 2014:128046.</a></li><li><a class="nounderline abstract_t">Larrocha C, Fernández de Castro M, Fontan G, et al. Hereditary myeloperoxidase deficiency: study of 12 cases. Scand J Haematol 1982; 29:389.</a></li><li><a class="nounderline abstract_t">Milligan KL, Mann D, Rump A, et al. Complete Myeloperoxidase Deficiency: Beware the "False-Positive" Dihydrorhodamine Oxidation. J Pediatr 2016; 176:204.</a></li><li><a class="nounderline abstract_t">Ferre EM, Rose SR, Rosenzweig SD, et al. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight 2016; 1.</a></li><li><a class="nounderline abstract_t">Yoshida A, Beutler E, Motulsky AG. Human glucose-6-phosphate dehydrogenase variants. Bull World Health Organ 1971; 45:243.</a></li><li><a class="nounderline abstract_t">Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin North Am 2016; 30:373.</a></li><li class="breakAll">Dinauer M. The phagocyte system and disorders of granulopoiesis and granulocyte function.. In: Nathan and Oski's hematology of infancy and childhood, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.889.</li><li><a class="nounderline abstract_t">Ardati KO, Bajakian KM, Tabbara KS. Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function. Acta Haematol 1997; 97:211.</a></li><li class="breakAll">Lazzato L. Glucose-6-phosphate dehydrogenase deficiency and hemolytic anemia. In: Nathan and Oski's hematology of infancy and childhood, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.704.</li><li><a class="nounderline abstract_t">Vives Corrons JL, Feliu E, Pujades MA, et al. Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona). Blood 1982; 59:428.</a></li><li><a class="nounderline abstract_t">Mamlok RJ, Mamlok V, Mills GC, et al. Glucose-6-phosphate dehydrogenase deficiency, neutrophil dysfunction and Chromobacterium violaceum sepsis. J Pediatr 1987; 111:852.</a></li><li><a class="nounderline abstract_t">Gray GR, Stamatoyannopoulos G, Naiman SC, et al. Neutrophil dysfunction, chronic granulomatous disease, and non-spherocytic haemolytic anaemia caused by complete deficiency of glucose-6-phosphate dehydrogenase. Lancet 1973; 2:530.</a></li><li><a class="nounderline abstract_t">Roos D, van Zwieten R, Wijnen JT, et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999; 94:2955.</a></li><li><a class="nounderline abstract_t">van Bruggen R, Bautista JM, Petropoulou T, et al. Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 2002; 100:1026.</a></li><li><a class="nounderline abstract_t">Spolarics Z, Siddiqi M, Siegel JH, et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med 2001; 29:728.</a></li><li><a class="nounderline abstract_t">Njålsson R, Ristoff E, Carlsson K, et al. Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency. Hum Genet 2005; 116:384.</a></li><li><a class="nounderline abstract_t">Spielberg SP, Boxer LA, Oliver JM, et al. Altered phagocytosis and microtubule function in leukocytes from a patient with severe glutathione synthase deficiency (5-oxoprolinuria). Monogr Hum Genet 1978; 9:90.</a></li><li><a class="nounderline abstract_t">Baehner RL, Boxer LA. Role of membrane vitamin E and cytoplasmic glutathione in the regulation of phagocytic functions of neutrophils and monocytes. Am J Pediatr Hematol Oncol 1979; 1:71.</a></li><li><a class="nounderline abstract_t">Xia H, Ye J, Wang L, et al. A case of severe glutathione synthetase deficiency with novel GSS mutations. Braz J Med Biol Res 2018; 51:e6853.</a></li><li class="breakAll">Baylor Research Institute, Institute of Metabolic Disease, Dallas; Duke University Medical Center, Pediatric Biochemical Genetics Laboratory. www.baylorhealth.edu/imd (Accessed on May 11, 2007).</li><li><a class="nounderline abstract_t">Simon E, Vogel M, Fingerhut R, et al. Diagnosis of glutathione synthetase deficiency in newborn screening. J Inherit Metab Dis 2009; 32 Suppl 1:S269.</a></li><li><a class="nounderline abstract_t">Ristoff E, Larsson A. Inborn errors in the metabolism of glutathione. Orphanet J Rare Dis 2007; 2:16.</a></li><li><a class="nounderline abstract_t">Boxer LA, Oliver JM, Spielberg SP, et al. Protection of granulocytes by vitamin E in glutathione synthetase deficiency. N Engl J Med 1979; 301:901.</a></li><li><a class="nounderline abstract_t">Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr 2001; 139:79.</a></li><li><a class="nounderline abstract_t">Janecke AR, Mayatepek E, Utermann G. Molecular genetics of type 1 glycogen storage disease. Mol Genet Metab 2001; 73:117.</a></li><li><a class="nounderline abstract_t">Melis D, Fulceri R, Parenti G, et al. Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature. Eur J Pediatr 2005; 164:501.</a></li><li><a class="nounderline abstract_t">Anderson DC, Mace ML, Brinkley BR, et al. Recurrent infection in glycogenosis type Ib: abnormal neutrophil motility related to impaired redistribution of adhesion sites. J Infect Dis 1981; 143:447.</a></li><li><a class="nounderline abstract_t">Kilpatrick L, Garty BZ, Lundquist KF, et al. Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest 1990; 86:196.</a></li><li><a class="nounderline abstract_t">Ma R, Moein Vaziri F, Sabino GJ, et al. Glycogen Storage Disease Ib and Severe Periodontal Destruction: A Case Report. Dent J (Basel) 2018; 6.</a></li><li><a class="nounderline abstract_t">Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur J Pediatr 2002; 161 Suppl 1:S88.</a></li><li><a class="nounderline abstract_t">Melis D, Parenti G, Della Casa R, et al. Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs. Acta Paediatr 2003; 92:1415.</a></li><li><a class="nounderline abstract_t">Melis D, Pivonello R, Parenti G, et al. Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I. J Pediatr 2007; 150:300.</a></li><li><a class="nounderline abstract_t">Melis D, Balivo F, Della Casa R, et al. Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders? J Inherit Metab Dis 2008; 31 Suppl 2:S227.</a></li><li><a class="nounderline abstract_t">Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001; 97:376.</a></li><li><a class="nounderline abstract_t">McCawley LJ, Korchak HM, Douglas SD, et al. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization. Pediatr Res 1994; 35:84.</a></li><li><a class="nounderline abstract_t">Donadieu J, Bader-Meunier B, Bertrand Y, et al. Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases. Nouv Rev Fr Hematol 1994; 35:529.</a></li><li><a class="nounderline abstract_t">Yamaguchi T, Ihara K, Matsumoto T, et al. Inflammatory bowel disease-like colitis in glycogen storage disease type 1b. Inflamm Bowel Dis 2001; 7:128.</a></li><li><a class="nounderline abstract_t">Dale DC, Bolyard AA, Marrero T, et al. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor. Curr Opin Hematol 2019; 26:16.</a></li><li><a class="nounderline abstract_t">Li AM, Thyagu S, Maze D, et al. Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length. Pediatr Hematol Oncol 2018; 35:45.</a></li><li><a class="nounderline abstract_t">Simmons PS, Smithson WA, Gronert GA, Haymond MW. Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. J Pediatr 1984; 105:428.</a></li><li><a class="nounderline abstract_t">Pinsk M, Burzynski J, Yhap M, et al. Acute myelogenous leukemia and glycogen storage disease 1b. J Pediatr Hematol Oncol 2002; 24:756.</a></li><li><a class="nounderline abstract_t">Grünert SC, Derks TGJ, Adrian K, et al. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. Genet Med 2022; 24:1781.</a></li><li><a class="nounderline abstract_t">Kwon JH, Lee YM, Cho JH, et al. Liver-directed gene therapy for murine glycogen storage disease type Ib. Hum Mol Genet 2017; 26:4395.</a></li><li><a class="nounderline abstract_t">Chou JY, Cho JH, Kim GY, Mansfield BC. Molecular biology and gene therapy for glycogen storage disease type Ib. J Inherit Metab Dis 2018; 41:1007.</a></li><li><a class="nounderline abstract_t">Rake JP, Visser G, Labrune P, et al. Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002; 161 Suppl 1:S112.</a></li></ol></div><div id="topicVersionRevision">Topic 3954 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6267975" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myeloperoxidase deficiency: prevalence and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6260268" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hereditary myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6189859" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23066164" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Myeloperoxidase: a front-line defender against phagocytosed microorganisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15108282" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Genetic characterization of myeloperoxidase deficiency in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32758448" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9766845" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical manifestation of myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3006224" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Myeloperoxidase-deficient polymorphonuclear leucocytes (VII): Incidence in untreated myeloproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27013444" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27013444" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787133" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26904693" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of Myeloperoxidase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974816" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2165113" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6253527" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2825109" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Myeloperoxidase deficiency with extensive candidal osteomyelitis of the base of the skull.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846651" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Myeloperoxidase deficiency as a predisposing factor for deep mucocutaneous candidiasis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381226" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Candida albicans meningitis in a child with myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114158" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Myeloperoxidase deficiency manifesting as pustular candidal dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11055615" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Disseminated fungal infection associated with myeloperoxidase deficiency in a premature neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5796360" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/217268" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Leukocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698675" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386020" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Immunological parameters of candidiasis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11111115" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11916266" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Growing significance of myeloperoxidase in non-infectious diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17850484" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : How human neutrophils kill and degrade microbes: an integrated view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24631667" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Myeloperoxidase deficiency attenuates nitrogen mustard-induced skin injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24990898" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Myeloperoxidase deficiency ameliorates progression of chronic kidney disease in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24707472" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Endothelial function in a mouse model of myeloperoxidase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6296995" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hereditary myeloperoxidase deficiency: study of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27301573" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Complete Myeloperoxidase Deficiency: Beware the "False-Positive" Dihydrorhodamine Oxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27588307" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5316621" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Human glucose-6-phosphate dehydrogenase variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040960" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Glucose-6-Phosphate Dehydrogenase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040960" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Glucose-6-Phosphate Dehydrogenase Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158663" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9158663" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7055648" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3681551" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Glucose-6-phosphate dehydrogenase deficiency, neutrophil dysfunction and Chromobacterium violaceum sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4125296" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Neutrophil dysfunction, chronic granulomatous disease, and non-spherocytic haemolytic anaemia caused by complete deficiency of glucose-6-phosphate dehydrogenase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556177" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130518" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11373456" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15717202" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/732856" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Altered phagocytosis and microtubule function in leukocytes from a patient with severe glutathione synthase deficiency (5-oxoprolinuria).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/396794" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role of membrane vitamin E and cytoplasmic glutathione in the regulation of phagocytic functions of neutrophils and monocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29340523" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A case of severe glutathione synthetase deficiency with novel GSS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29340523" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A case of severe glutathione synthetase deficiency with novel GSS mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19728142" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnosis of glutathione synthetase deficiency in newborn screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397529" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inborn errors in the metabolism of glutathione.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/481537" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Protection of granulocytes by vitamin E in glutathione synthetase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445798" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term clinical outcome in patients with glutathione synthetase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11386847" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Molecular genetics of type 1 glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15906092" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6939755" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recurrent infection in glycogenosis type Ib: abnormal neutrophil motility related to impaired redistribution of adhesion sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2164043" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30282931" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Glycogen Storage Disease Ib and Severe Periodontal Destruction: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373579" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association of glycogen storage disease 1b and Crohn disease: results of a North American survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14971792" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17307551" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18437526" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11154211" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7510873" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7512258" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11383585" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inflammatory bowel disease-like colitis in glycogen storage disease type 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30451720" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29652549" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6590826" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12468919" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Acute myelogenous leukemia and glycogen storage disease 1b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35503103" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973635" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Liver-directed gene therapy for murine glycogen storage disease type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29663270" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Molecular biology and gene therapy for glycogen storage disease type Ib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373584" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
